Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories


Vertex Urged To Target Major M&A After Another Rare Disease Failure

After the failure of a second candidate for alpha-1 antitrypsin deficiency, Vertex may have to put its cash reserves to use in M&A.

Companies Rare Diseases Commercial

New Data Reinforces Potential Of Sanofi's Sutimlimab After Shock FDA Snub

Having suffered a setback last year when deficiencies at a third-party manufacturer scuppered hopes of a quick US approval of sutimlimab for cold agglutinin disease, Sanofi has released more promising data on its C1s inhibitor at the European Hematology Association meeting.

Blood & Coagulation Disorders Clinical Trials Rare Diseases

Doctors Frustrated By Lack Of Guidance On Who Should Get Aduhelm

Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.

Neurology Launches Market Access

Coronavirus Spotlight

Does New Study Question Need for Pediatric COVID-19 Vaccines?

A recent study says a cohort of unvaccinated individuals aged under 16 years in Israel showed a nearly two-fold decrease in COVID-19 positivity for each 20 percentage points of individuals vaccinated overall. As Pfizer, Moderna and Bharat Biotech develop pediatric vaccines, should they consider if herd immunity might make such vaccines redundant?

Research & Development Coronavirus COVID-19

Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.

Scrip Podcast


Recent Tweets from Scrip


 

Infographics

Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge

From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.

India Coronavirus COVID-19

The 2021 Worldwide Pharma And Biotech R&D Scene

INFOGRAPHIC: A snapshot of the industry in key performance indicators surrounding R&D taken in early 2021.

Companies Market Intelligence

Pandemic Perspectives: China Vaccine Diplomacy - A World On Shots

Over 50 countries around the world are now receiving COVID-19 vaccine deliveries from China, totaling 3.3 million doses and counting so far. This Scrip infographic shows their locations, quantity of supplies and the developers involved.

China Coronavirus COVID-19

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

How Cipla Is Shaping Lung Leadership Beyond Asthma, AMR Plans

CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.

Commercial Business Strategies

Pioneering Japan Approval For Daiichi’s Oncolytic Virus In Glioma

Japan grants ground-breaking approval for Daiichi oncolytic virus in brain cancer on condition of additional data. The nod marks another step forward in the firm's strategic global pivot to oncology. 

Japan Approvals

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.

Clinical Trials Approvals

Finance Watch: Janux Offering Makes 47 Biopharma IPOs In 2021, So Far

Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.

Finance Watch Financing

Aduhelm Approval Is Breakthrough For Neurimmune, Company Which Discovered It

The co-founder of the Swiss company which discovered aducanumab looks back over its 20 year wait for approval, and ahead to future growth plans.

Neurology Commercial

Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s

Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.

Deals Business Strategies
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Latest From Policy & Regulation, Policy & Regulation

US 500m Dose Donation Takes Shine From China Vaccine Diplomacy

The Biden Administration’s pledge to provide 500 million doses of Pfizer/BioNTech's COVID-19 vaccines is a direct blow to China’s global vaccine diplomacy push.

China Coronavirus COVID-19

Coronavirus Update: Brazil Opens Up Vaccine Imports

Brazil is permitting imports of additional coronavirus vaccines, while in India, Serum Institute will manufacture Sputnik V, the government is unifying vaccine sourcing, and emergency use approval has been granted to Lilly's anti-COVID-19 antibodies. 

Commercial Policy

Pharma Missing Out From Market Access Challenges In China: EU Group

Slower approvals for foreign drugs, a volume-based procurement scheme and localization requirements caused nearly 80% of respondent European pharma firms to miss out on opportunities in China, where they also continue to decouple from headquarters in a “in China-for-China” strategy, a survey from a prominent EU business group shows.

China Market Access
See All

Research & Development Explore this Topic

Set Alert for Research & Development

Latest From Research & Development

Does New Study Question Need for Pediatric COVID-19 Vaccines?

A recent study says a cohort of unvaccinated individuals aged under 16 years in Israel showed a nearly two-fold decrease in COVID-19 positivity for each 20 percentage points of individuals vaccinated overall. As Pfizer, Moderna and Bharat Biotech develop pediatric vaccines, should they consider if herd immunity might make such vaccines redundant?

Research & Development Coronavirus COVID-19

BMS's Rebloyzl Data Supports Adding Less Severe Patients To Label

Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.

Clinical Trials Blood & Coagulation Disorders

Pipeline Watch: The Bumper ASCO Edition

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All
UsernamePublicRestriction

Register